- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14.02. | First self-amplifying mRNA vaccine reaches Europe | ||
| 14.02. | EU approves CSL's once-monthly HAE drug Andembry | ||
| 14.02. | BMS study of Opdualag in adjuvant melanoma ends in failure | ||
| 14.02. | Apple study will look at the role tech can play in health | ||
| 14.02. | RFK Jr-led commission will assess 'threats' to children | ||
| 13.02. | Kennedy confirmed as HHS Secretary | ||
| 13.02. | Santhera's DMD drug poised for wider rollout in Germany | ||
| 13.02. | Sanofi, J&J abandon trial of E coli vaccine after poor data | ||
| 13.02. | FDA changes its mind on Astellas' geographic atrophy drug | ||
| 13.02. | Small study finds GLP-1 drug can curb excess alcohol use | ||
| 13.02. | Ex-DeepMind scientist launches drug discovery company | ||
| 12.02. | Abcuro raises $200m to take muscle disease drug to market | ||
| 12.02. | With Merck circling, SpringWorks gets new drug approval | ||
| 12.02. | BridgeBio gets EU nod for ATTR cardiomyopathy drug | ||
| 12.02. | Storybook can help kids understand rare kidney disease | ||
| 12.02. | Trump 'fired Inspector General over critical USAID report' | ||
| 11.02. | Novartis builds in cardiovascular with $3.1bn Anthos buy | ||
| 11.02. | Ten years on, Roche jettisons InterMune and Esbriet in US | ||
| 11.02. | Merck confirms its interest in buying SpringWorks | ||
| 11.02. | Ten years on, Roche jettisons InterMune and Esbriet | ||
| 11.02. | Boehringer drug scores in another pulmonary fibrosis trial | ||
| 11.02. | Judge orders block on Trump's NIH funding cuts | ||
| 10.02. | Pliant slumps on decision to pause lung disease drug trial | ||
| 10.02. | Industry steps up as EU debates an action plan for AI | ||
| 10.02. | FDA clears new antibiotic for superbug infections |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
